Evidence map›Paper›PMID 30567996›Full record

ArticleJournal of virology2019

Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.

Batsirai M Mabvakure, Cathrine Scheepers, Nigel Garrett, Salim Abdool Karim, Carolyn Williamson, Lynn Morris, Penny L Moore

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Antigenic Variability.Frontiers in immunology · 2020
    Article
  9. The antibody response in HIV-1-infected donors.Current opinion in HIV and AIDS · 2019
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Batsirai M MabvakureCenter for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Cathrine ScheepersCenter for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Nigel GarrettCentre for the AIDS Programme of Research in South Africa (CAPRISA), KwaZulu Natal, South Africa.
Salim Abdool KarimCentre for the AIDS Programme of Research in South Africa (CAPRISA), KwaZulu Natal, South Africa.
Carolyn WilliamsonCentre for the AIDS Programme of Research in South Africa (CAPRISA), KwaZulu Natal, South Africa.
Lynn MorrisCenter for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
Penny L MooreCenter for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa pennym@nicd.ac.za.ORCID 0000-0001-8719-4028
National Health Laboratory Service · ZACentre for the AIDS Programme of Research in South Africa · ZAUniversity of Cape Town · ZA

Funding

The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
CAPRISA HIV-1 neutralizing antibodies: Harnessing ontogeny for immunogen designU01AI116086 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI KWONG, PETER D, MASCOLA, JOHN R · 2015 to 2019
$874k
NIAID NIH HHS U01 AI116086NIAID NIH HHS U19 AI051794
6 · The paper itself

Abstract

The development of HIV broadly neutralizing antibodies (bNAbs) has previously been shown to be associated with viral evolution and high levels of genetic diversity in the HIV envelope (Env) glycoprotein. However, few studies have examined Env evolution in those who fail to develop neutralization breadth in order to assess whether bNAbs result from distinct evolutionary pathways. We compared Env evolution in eight HIV-1-infected participants who developed bNAbs to six donors with similar viral loads who did not develop bNAbs over three years of infection. We focused on Env V1V2 and C3V4, as these are major targets for both strain-specific neutralizing antibodies (nAbs) and bNAbs. Overall evolutionary rates (ranging from 9.92 × 10

Indexed as

Antibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitope MappingEpitopesFemaleHIV-1HIV AntibodiesHIV InfectionsHumansImmunizationPlasmaAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusEpitopesHIV Antibodiesbroadly neutralizing antibodiesenvelope glycoproteinepitope diversityHIV-1 intrapatient evolutionHIV vaccinesequential vaccination

Identifiers

PMID30567996
PMCPMC6401460
OpenAlexW2904578259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.